Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/142371
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Detection and drivers of exposure and effects of pharmaceuticals in higher vertebrates |
Autor: | Shore, Richard F.; Taggart, Mark A. CSIC ORCID; Smits, Judit; Mateo, Rafael CSIC ORCID ; Richards, Ngaio L.; Fryday, Steve | Palabras clave: | Wildlife toxicology Risk assessment Sentinel species Emerging contaminants Environmental monitoring Ecopharmacovigilance |
Fecha de publicación: | 2014 | Editor: | Royal Society (Great Britain) | Citación: | Philosophical Transactions B: Biological Sciences 369(1656): 20130570 (2014) | Resumen: | Pharmaceuticals are highly bioactive compounds now known to be widespread environmental contaminants. However, research regarding exposure and possible effects in non-target higher vertebrate wildlife remains scarce. The fate and behaviour of most pharmaceuticals entering our environment via numerous pathways remain poorly characterized, and hence our conception and understanding of the risks posed to wild animals is equally constrained. The recent decimation of Asian vulture populations owing to a pharmaceutical (diclofenac) offers a notable example, because the exposure route (livestock carcasses) and the acute toxicity observed were completely unexpected. This case not only highlights the need for further research, but also the wider requirement for more considered and comprehensive ‘ecopharmacovigilance’. We discuss known and potential high risk sources and pathways in terrestrial and freshwater ecosystems where pharmaceutical exposure in higher vertebrate wildlife, principally birds and mammals, may occur. We examine whether approaches taken within existing surveillance schemes (that commonly target established classes of persistent or bioaccumulative contaminants) and the risk assessment approaches currently used for pesticides are relevant to pharmaceuticals, and we highlight where new approaches may be required to assess pharmaceutical-related risk. | Versión del editor: | https://doi.org/10.1098/rstb.2013.0570 | URI: | http://hdl.handle.net/10261/142371 | DOI: | 10.1098/rstb.2013.0570 | Identificadores: | doi: 10.1098/rstb.2013.0570 e-issn: 1471-2970 issn: 0962-8436 |
Aparece en las colecciones: | (IREC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
pharmaceuticalsvertebrate.pdf | 553,64 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
11
checked on 11-abr-2024
SCOPUSTM
Citations
79
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
67
checked on 27-feb-2024
Page view(s)
199
checked on 17-abr-2024
Download(s)
236
checked on 17-abr-2024